Evidence map›Paper›PMID 33615327›Full record

ArticleAmerican journal of epidemiology2021

Transporting Subgroup Analyses of Randomized Controlled Trials for Planning Implementation of New Interventions.

Megha L Mehrotra, Daniel Westreich, M Maria Glymour, Elvin Geng, David V Glidden

Abstract read
In one paragraph

Article in American journal of epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Megha L Mehrotra
Daniel Westreich
M Maria Glymour
Elvin Geng
David V Glidden

Funding

Chemoprophylaxis for HIV Prevention in Men SupplementU01AI064002 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2005 to 2011
$41.3M
From patients to policy: innovative epidemiology for implementation scienceDP2HD084070 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WESTREICH, DANIEL J · 2014 to 2014
$2.3M
MENTORING MULTIDISCIPLINARY PATIENT-ORIENTED RESEARCH IN ENGAGEMENT IN HIV CAREK24AI134413 · NIAID · WASHINGTON UNIVERSITY · PI Elvin H. Geng · 2017 to 2026
$1.4M
Transportability of Causal Effects to Inform HIV Pre-exposure Prophylaxis ImplementationF31MH111346 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MEHROTRA, MEGHA LYNNE · 2016 to 2018
$116k
NIAID NIH HHS K24 AI134413NIAID NIH HHS U01 AI064002NICHD NIH HHS DP2 HD084070NIMH NIH HHS F31 MH111346
6 · The paper itself

Abstract

Subgroup analyses of randomized controlled trials guide resource allocation and implementation of new interventions by identifying groups of individuals who are likely to benefit most from the intervention. Unfortunately, trial populations are rarely representative of the target populations of public health or clinical interest. Unless the relevant differences between trial and target populations are accounted for, subgroup results from trials might not reflect which groups in the target population will benefit most from the intervention. Transportability provides a rigorous framework for applying results derived in potentially highly selected study populations to external target populations. The method requires that researchers measure and adjust for all variables that 1) modify the effect of interest and 2) differ between the target and trial populations. To date, applications of transportability have focused on the external validity of overall study results and understanding within-trial heterogeneity; however, this approach has not yet been used for subgroup analyses of trials. Through an example from the Iniciativa Profilaxis Pre-Exposición (iPrEx) study (multiple countries, 2007-2010) of preexposure prophylaxis for human immunodeficiency virus, we illustrate how transporting subgroup analyses can produce target-specific subgroup effect estimates and numbers needed to treat. This approach could lead to more tailored and accurate guidance for resource allocation and cost-effectiveness analyses.

Indexed as

Data Interpretation, StatisticalResearch DesignAdultCost-Benefit AnalysisHealth Care RationingHIV InfectionsHomosexuality, MaleHumansMalePre-Exposure ProphylaxisRandomized Controlled Trials as TopicReproducibility of ResultsSocioeconomic Factorsexternal validityimplementationnumber needed to treatsubgroup analysestarget-specific subgroup analysestransportability

Identifiers

PMID33615327
PMCPMC8489435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.